Meet the Researcher: Modeline Longjohn

Share

Dr. Modeline Longjohn is a postdoctoral fellow in the Department of Anatomy & Cell Biology at
Western University. She is conducting BCC-funded breast cancer research under the
mentorship of Dr. Alison Allan.

  1. Could you share your motivation/personal connection to breast cancer research?
    I am motivated by the suffering and pain that a breast cancer diagnosis can bring both to the
    patient and their family and friends. I have experienced some of this pain due to my own
    friends who have had breast cancer diagnoses. Specifically, two decades ago, I lost a close
    family friend to breast cancer and lost another friend a decade later. In both cases, early
    detection and better treatment options would have saved their lives. Therefore, every day I am
    involved in breast cancer research, I do it as a tribute to those affected by breast cancer, and to
    contribute towards a future where no one dies from breast cancer.
  2. What specific areas of breast cancer research are you currently focusing on, and why are
    they important?

    My research is focused on triple negative breast cancer – the breast cancer subtype with the
    worst outcome. This type of breast cancer has the tendency to spread (or metastasize) and
    affects women from ethnic minorities more than other subtypes. In addition, triple negative
    breast cancer currently has limited treatment options once it spreads. My research is focused
    on investigating which proteins triple negative breast cancer cells may use to spread to
    different organs such as the bone, brain, and lung. I am using a sophisticated technology called
    proteomics to look at organ-specific protein changes, particularly in response to normal and
    low oxygen, which can affect metastasis. The functions of the identified proteins will then be
    tested using special assays, to understand their importance in breast cancer spread. In the
    future, the results of this research could identify new ways to predict and manage the
    preferential spread of breast cancer cells to specific organs.
  3. What recent breakthroughs or discoveries in Canadian breast cancer research are exciting
    to you?

    A researcher at McGill University is currently working on developing new blood biomarkers for
    monitoring response to therapy. This technique is called liquid biopsy. Using this method,
    patients can be checked in real-time to ascertain if the treatment is working or not. This can
    allow for a more tailored treatment plan instead of the traditional one-size-fits-all model, which
    doesn’t work for every patient. I am excited about this, because my area of research could lead
    to also developing new tools for liquid biopsy – specifically for predicting and managing cancer
    spread, an area that desperately needs fresh solutions.
  4. How do you see the future of breast cancer prevention, screening, diagnosis, treatment
    evolving through research?

    In my opinion, the future of breast cancer is liquid biopsy and precision/personalized medicine.
    I envision the use of simple blood tests to detect breast cancer early, leading to more effective
    screening and early diagnosis. Liquid biopsy will be used to develop a precise/personalized treatment plan, based on the patient’s biology/genetics, leading to much better outcomes. The research to make this possible is currently underway in labs across Canada (and globally), including at the Allan lab, where my research is taking place.
  5. In your opinion, what role can public awareness and advocacy play in advancing breast cancer research and treatment?
    Public awareness is essential for the public to have accurate information about screening, early detection, and symptoms to watch out for. Public advocacy is also important, as it facilitates the fundraising process (which provides much needed funding for cancer research), and promotes legislation that improves policies and modalities surrounding research and treatment.

Related Articles

Metastatic Breast Cancer: ESMO 2026

Metastatic Breast Cancer (MBC) dominated much of the conversation at ESMO 2026, and for good reason. As treatment landscapes expand and different types of breast

Progress Through Research

Latest Research

Breast Cancer Canada donations fund life-saving research that directly impacts Canadian patients. That means better answers, bigger breakthroughs – and more personalized treatment for every breast cancer diagnosis.

Patient Tools

Our suite of digital tools are each designed to help individuals better manage their breast cancer journey through education, research and personalized insights, while also elevating the patient voice.

Patient Stories

Every breast cancer journey is unique, but together, these stories paint a powerful picture of progress. Through firsthand accounts from patients and survivors, we share stories that highlight the lived-experiences of breast cancer.

Fuel Progress

Progress happens when we invest in it. Canada is home to some of the world’s brightest minds in research. Together, we are advancing science, ensuring it leads to earlier detection, better treatments, and improved outcomes for patients across the country.

Sign Up, Know More